Clinical Cancer Research Holland
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kondo, M.
Right arrow Articles by Monden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kondo, M.
Right arrow Articles by Monden, M.
Clinical Cancer Research Vol. 5, 4005-4012, December 1999
© 1999 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma1

Motoi Kondo, Hirofumi Yamamoto, Hiroaki Nagano, Jiro Okami, Yasuhiro Ito, Junzo Shimizu, Hidetoshi Eguchi, Atsushi Miyamoto, Keizo Dono, Koji Umeshita, Nariaki Matsuura, Ken-ichi Wakasa, Shoji Nakamori, Masato Sakon2 and Morito Monden

Department of Surgery II, Osaka University Medical School, Osaka 505-0871, Japan [M. K., H. Y., H. N., J. O., Y. I., J. S., H. E., A. M., K. D., K. U., S. N., M. S., M. M]; Department of Pathology, School of Allied Health Science, Faculty of Medicine, Osaka University, Osaka, Japan 565-0871 [Y. I., N. M.]; and Department of Pathology, Osaka City University Hospital, Osaka, 545-0051 Japan [K. W.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81%) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88%). In HCC, 17% of samples displayed a high COX-2 expression, and 37% of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription-PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Primary HCC3 is one of the most common tumors in Southeast Asia and Africa, where the incidence of this disease is ~30 per 100,000 men/year. The prognosis of HCC is generally poor, and the 5-year survival rate is limited to 25–39% after surgery (1) . Many investigators have reported a putative link between infection with hepatitis B or C, liver cirrhosis, and the development of HCC. Hepatic cirrhosis is observed in up to 90% of patients with HCC (2) . In the United States, it has been estimated that 60–90% of those infected with HCV each year develop chronic hepatitis C, which often leads to cirrhosis. The result is often liver failure or liver cancer. Chronic hepatitis C is the leading cause of liver cancer in the United States and, according to the American Liver Foundation, is the chief reason for liver transplantation. Also in Japan, HCV-based cirrhosis is a serious problem because it develops to HCC at a ratio of 7% per year, and it is found in 70% of HCCs (3) .

COX is the rate-limiting enzyme involved in the conversion of arachidonic acid to prostaglandin H2, the precursor of various compounds including prostaglandins, prostacyclin, and thromboxanes. Two COX genes, COX-1 and COX-2, have been identified that share >60% identity at the amino acid level (4) . COX-1 is constitutively expressed in many tissues and responsible for various physiological functions including cytoprotection of the stomach, vasodilatation in the kidney, and production of a proaggregatory prostanoid, thromboxane A2, by platelets. On the other hand, COX-2 is an inducible immediate-early gene originally found to be induced by various stimuli, such as mitogens and cytokines, and growth factors (5, 6, 7) . Overexpression of COX-2 has been demonstrated in various chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and gastritis caused by Helicobacter pylori (8, 9, 10) .

Recent studies have highlighted the relevance of COX-2 in human carcinogenesis. Epidemiological studies indicate that NSAIDs lead to a regression of colonic polyps in patients with familial adenomatous polyposis (11) . NSAIDs are also known to reduce the risk of sporadic colorectal cancers and breast and lung cancers (12, 13) . Because NSAIDs can inhibit activities of both COX-1 and COX-2, and double knock-out mice for the adenomatous polyposis coli and COX-2 genes showed marked reduction in the size and frequency of intestinal polyps, it is suggested that the antitumor effect of NSAIDs is attributable, at least in part, to inhibition of COX-2 (14 , 15) . In fact, the expression of COX-2 is significantly increased in various types of carcinoma, including HCC (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28) . There is also sufficient evidence from animal studies indicating that selective COX-2 inhibitors produce effective prevention of carcinogenesis and that these compounds act by induction of apoptosis of various cancer cells (29, 30, 31, 32, 33, 34, 35, 36, 37, 38) . These findings suggest that COX-2 may be involved in carcinogenesis and/or progression of certain types of human malignancies. In human hepatocellular carcinoma, COX-2 expression has been shown to be associated with differentiated phenotype (16, 17) . However, COX-2 expression in the premalignant hepatic dysplasia and the impact of COX-2 expression on clinical course have not yet been elucidated.

In an effort to determine the prognostic value of COX-2 expression in both tumor and nontumor tissues, we examined the level of COX-2 mRNA by RT-PCR and extent of COX-2 protein by immunohistochemistry in HCV-infected HCCs and their associated nontumor tissues. A subset of dysplastic lesions was also assessed in this study.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines and Tissue Samples.
Three HCC cell lines, HuH7, HLE, and HLF were obtained from the Japanese Cancer Research Resources Bank. Cells were cultured in DMEM supplemented with 10% FCS at 37°C. Tissue samples were obtained from 61 patients with hepatic tumors, who underwent hepatectomy at the Department of Surgery II, Osaka University Medical School. All patients had HCV infection, but none had hepatitis B viral infection. The mean follow-up period for the patients’ prognosis was 3.4 ± 2.0 years. Various hepatic lesions were immunohistochemically examined for COX-2 expression, including 8 dysplasias and 53 paired HCCs. Nontumor tissues were also examined, which comprised 21 CH-based livers and 32 cirrhotic livers. Prior to hepatectomy for HCC, 15 patients were treated with TAE. Nine histologically normal livers devoid of hepatitis B or C viral infection were obtained from nine patients with liver metastasis of colorectal cancer and served as control.

For immunohistochemistry, tissue samples were fixed in 10% neutral buffered formalin, processed through graded ethanol, and embedded in paraffin. Tissue samples were immediately frozen in liquid nitrogen and stored at -80°C for analysis by RT-PCR and Western blotting.

Pathological Examination.
Tissue sections (4-µm thick) were deparaffinized in xylene, rehydrated, and stained with H&E solution. Pathological diagnosis of tissues into nontumor and tumor tissues was determined by a skilled pathologist (K. W.), who was blinded to the clinical background. For 53 nontumor tissues, the presence of active inflammation and cirrhotic nodule was examined. Tumor tissues were examined for the following characteristics: cell differentiation (well, moderately, or poorly differentiated), number of tumors, capsular formation, septal formation, capsular invasion, portal vein tumor thrombus formation, and hepatic vein invasion.

Semiquantitative RT-PCR.
RNA extraction was carried out with TRIzol reagent in a single-step method, and cDNA was generated with avian myeloblastosis virus reverse transcriptase (Promega Corp., Madison, WI), as described previously (39) . Semiquantitative analysis for expression of COX-2 mRNA was performed by the multiplex RT-PCR technique, using a housekeeping gene, PBGD, as an internal standard (28 , 40, 41) . To minimize the differences of inter-PCRs, PCR was performed with COX-2 and PBGD primers in an identical tube, under unsaturated conditions. PCR was performed in a 25-µl reaction mixture containing 1 µl of cDNA template, 1 x Perkin-Elmer PCR buffer, 1.5 mM MgCl2, 0.8 mM deoxynucleotide triphosphates, 0.8 µM of each primer for COX-2, 80 nM each for PBGD, and 1 unit of Taq DNA polymerase (AmpliTaq Gold; Roche Molecular Systems, Inc., Branchburg, NJ). The PCR primers used for detection of COX-2 and PBGD cDNAs were synthesized as reported previously, and the amplified products were 305 and 127 bp, respectively (42 , 43) . The condition for multiplex PCR was set up as follows: one cycle of denaturing at 95°C for 12 min, followed by 35–40 cycles of 95°C for 1 min, and 72°C for 1 min, before a final extension at 72°C for 10 min. The electrophoresed PCR products were scanned by densitometry, and the relative value of the COX-2 band to PBGD band was calculated in each sample.

Reagents.
Rabbit polyclonal antihuman COX-2 antibody (23 , 28) and its blocking peptide that was used as immunogen (17 amino acids: position 251–267) for generation of this antibody were obtained from IBL Co. (Gunma, Japan). Recombinant COX-2 protein was obtained from Cayman Chemical (Ann Arbor, MI) and used as a positive control in Western blot analysis.

Immunohistochemistry.
After deparaffinization, heat antigen retrieval was performed as described previously (44) . The slides were then processed for immunohistochemistry on the TeckMate Horizon automated staining system (Dako, Carpinteria, CA; Refs. 28 and 45 ), using the Vectastain ABC-peroxidase kit (Vector Labs, Burlingame, CA; Ref. 44 ). In the step of primary antibody reaction, the slides were incubated with the COX-2 antibody (final concentration, 5 µg/ml) for 1 h at room temperature. For the positive controls, sections of colon cancer expressing COX-2 protein were included in each staining procedure. For negative controls, nonimmunized rabbit IgG (Vector Labs) or TBS (Tris-buffered saline) was used as a substitute for the primary antibody to verify the possibility of false-positive responses from nonspecific binding of IgG or from the secondary antibody. In addition, absorption tests were performed on tissue sections.

Evaluation of COX-2 Immunostaining.
All immunostained sections were evaluated in a blinded manner without knowledge of the clinical and pathological parameters. For each section, the intensity of staining was scored on a scale from 0 to 2, where 0 represented negative or faint staining; 1, moderate; and 2, strong staining. COX-2 expression was very faint or undetectable in the vascular epithelium, whereas epithelial cells of the bile ducts devoid of significant inflammation generally expressed moderate levels of COX-2. Accordingly, the latter level of staining was used as an inner control within the sample, which was designated arbitrarily as intensity level 1. COX-2 expression was generally homogeneous in each sample, except in 14 HCCs, in which tumor tissues were composed of more than two different histological types. In these cases, the carcinoma type that constituted the major volume of the tumor was selected as the representative type for evaluation. Staining was repeated at least twice to avoid possible technical errors, but similar results were obtained. All slides were interpreted by two investigators (H. Y. and Y. I.) on different occasions. The results of interpretation were similar except for <10% of the samples. The final diagnosis in the latter samples was determined by using a multihead microscope.

Western Blot Analysis.
Western blot analysis was performed as described previously (46) . Briefly, 100 µg of the total protein from tissues and 2.5 µg/ml COX-2 were used for this assay.

Statistical Analysis.
Statistical analysis was performed using the Statview J-4.5 program (Abacus Concepts, Inc., Berkeley, CA). The {chi}2 test and Fisher’s exact probability test or the log-rank test were used to examine the association between COX-2 expression and clinicopathological parameters or prognosis. P < 0.05 denoted the presence of a statistically significant difference.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Western Blot Analysis for COX-2.
To confirm the specificity of COX-2 antibody, a small set of tissue samples (three paired nontumor and tumor tissues and three normal livers) were subjected to Western blot analysis (Fig. 1)Citation . COX-2 antibody yielded a strong band to the control purified COX-2 protein (Fig. 1Citation , Lane 10). All three nontumor tissues with liver cirrhosis expressed clear bands for the COX-2 protein (Fig. 1Citation , Lanes 1, 3, and 5) and one well-differentiated HCC expressed COX-2 at a modest level (Lane 2). In contrast, COX-2 expression was not detected in two of poorly differentiated HCCs and three normal livers (Lanes 4, 6, and 7–9, respectively). When preabsorbed antibody was applied to the transferred membrane instead of the COX-2 antibody, no bands appeared on the blots (data not shown).



View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Western blot analysis for COX-2. Three paired nontumor and tumor tissues and three normal livers were examined for COX-2 expression. The nontumor tissues with liver cirrhosis expressed clear bands for the COX-2 protein (Lanes 1, 3, and 5). The well-differentiated HCCs expressed COX-2 at a modest level (Lane 2), but the poorly differentiated HCCs did not express COX-2 (Lanes 4 and 6). COX-2 expression was not detected in the three normal livers (Lanes 7–9). The recombinant COX-2 protein obtained from Cayman Chemical (Ann Arbor, MI) served as a positive control (Lane 10). When preabsorbed antibody, instead of the COX-2 antibody, was applied to the transferred membrane, no bands appeared on the blots (data not shown).

 
Immunohistochemical Analysis for COX-2.
Immunohistochemical staining of positive control sections of colon cancer expressing the COX-2 protein displayed a marked staining for COX-2 (Fig. 2A)Citation . In contrast, no staining was observed when the primary antibody was substituted with nonimmunized rabbit IgG or TBS (data not shown). Preabsorbed antibody with excess amount of immunogenes abolished staining on the sections (data not shown), indicating that the COX-2 antibody was highly specific to the COX-2 protein on tissue sections. Immunohistochemical assays were performed on a series of 53 paired HCCs and their matched nontumor tissues, 8 dysplasias, and 9 normal livers. The level of COX-2 showed a wide spectrum. Specifically, in normal livers, COX-2 expression was not detected, or moderate at the most, but CH-based hepatocytes expressed a moderate to strong COX-2 protein in all samples. The majority of cirrhotic livers (26 of 32; 81%) displayed a marked COX-2 expression. These results are summarized in Table 1Citation , and representative cases of each stage are shown in Fig. 2, B–DCitation . The difference in proportion of cells expressing a high level of COX-2 (intensity 2) between normal and cirrhotic livers was significant (P < 0.0001) as was that between CH and cirrhosis (P = 0.0001; Table 1Citation ). In tissue samples with dysplasia, COX-2 expression was mainly moderate or strong (7 of 8; 88%; Fig. 2ECitation ). In carcinoma tissues, 46 of 53 HCCs were evaluated because 7 HCCs were found to be completely necrotic, probably because of preoperative TAE treatment. In approximately one-half of examined cases (21 of 46; 46%), little or no staining was observed, whereas 17% of tissue samples (8 of 46) displayed a marked COX-2 expression (Fig. 2F)Citation , and 37% of cases (17 of 46) expressed moderate levels of COX-2 protein.



View larger version (189K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Immunohistochemical staining for COX-2. A, a positive control section of colon cancer expressing the COX-2 protein. Representative samples for each stage are shown in B–F. B, normal liver; C, chronic hepatitis; D, cirrhotic liver; E, dysplasia; F, HCC. A–F, x50. No staining was observed when the primary antibody was substituted by nonimmunized rabbit IgG or TBS (data not shown). Preabsorbed antibody with an excess amount of immunogens abolished the staining on the sections (data not shown).

 

View this table:
[in this window]
[in a new window]

  		Table 1 Immunohistochemical analysis of COX-2 expression

 
Correlation between COX-2 Expression and Clinicopathological Parameters.
The correlation between level of COX-2 expression in 46 HCCs and various clinicopathological features was examined (Table 2)Citation . For statistical analysis, cases were divided into two groups, high COX-2 expressors (intensity 2) and low COX-2 expressors (intensities 0 and 1). Inconsistent with previous reports (16 , 17) , there was a significant difference in COX-2 expression with regard to histological grade (Table 2)Citation . Thus, high COX-2 expression was associated with well- and moderately differentiated carcinomas (P = 0.019; Table 2Citation ). The correlation between COX-2 expression in HCC and disease-free period or overall survival rate was examined, but no significant relation was noted (data not shown).


View this table:
[in this window]
[in a new window]

  		Table 2 Relationship between COX-2 expression and clinicopathological parameters in cases with HCC

 
We also analyzed the relationship between COX-2 expression in nontumor tissues (21 chronic hepatitis and 32 cirrhosis) and disease-free survival time, because the nontumor tissues of liver are usually not normal but are pathological lesions. As shown in Fig. 3Citation , a striking difference in the disease-free survival time was found between high COX-2 expressors and low COX-2 expressors (P = 0.0132). To examine possible involvement of inflammation in COX-2 induction, 53 nontumor tissues were divided into two groups by pathological survey on their extent of inflammation (by K. W.). Active inflammation was noted in 3 of 21 CH-based livers and 29 of 32 cirrhosis. A significant correlation was found between high COX-2 expression in nontumor tissues and inflammation (P < 0.0001; Table 3Citation ).



View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Disease-free survival based on COX-2 expression in nontumor tissues. A striking difference in the disease-free survival time was found between high COX-2 expressors (intensity 2) and low COX-2 expressors (intensities 0 and 1; P = 0.0132). The mean follow-up period for the patients’ prognosis was 3.4 ± 2.0 years.

 

View this table:
[in this window]
[in a new window]

  		Table 3 Relationship between COX-2 expression and inflammation status in nontumor tissues

 
Semiquantitative RT-PCR.
To examine COX-2 mRNA levels, RT-PCR assay was performed in three HCC cell lines (HuH7, HLE, and HLF), two histologically normal livers, and six paired nontumor and tumor tissues. HuH7 and HLF cell lines expressed 305-bp bands for COX-2 with constitutive expression of PBGD, whereas the HLE cell line did not express a band for COX-2 (Fig. 4Citation , upper panel). In tissue samples, the relative value of COX-2 band to PBGD band was calculated for each lane (Fig. 4Citation , lower panel). In the normal livers, relatively weak levels of COX-2 mRNA were detected. In four of six paired samples (67%), nontumor tissues expressed higher levels of COX-2 mRNA than did the corresponding HCCs (cases 1, 3, 4, and 6), whereas one HCC expressed a higher COX-2 mRNA compared with the corresponding nontumor tissue (case 2). Tissue samples from one patient displayed scarce levels of COX-2 mRNA in both nontumor and tumor tissues (case 5). To avoid saturated PCR conditions, these assays were repeated with lower cycles of amplification, and similar results were obtained. Furthermore, the results of immunostaining and Western blot analysis were in agreement with those obtained by RT-PCR assay in each sample, suggesting that the expression of COX-2 protein is regulated at the transcription level (data not shown).



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. RT-PCR assays for COX-2 mRNA in the HCC cell lines and liver tissues. The HuH7 and HLF cell lines expressed 305-bp bands for COX-2 with constitutive expression of PBGD, whereas the HLE cell line did not express a band for COX-2 (upper panel). In the normal livers, relatively weak levels of COX-2 mRNA were detected. In four paired samples, nontumor tissues expressed higher levels of COX-2 mRNA than did corresponding HCCs (cases 1, 3 4, and 6), whereas one HCC expressed a higher COX-2 mRNA compared with the corresponding nontumor tissue (case 2). Tissue samples from one patient displayed scarce levels of COX-2 mRNA in both nontumor and tumor tissues (case 5; lower panel).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The present results showed that nontumor liver tissues often expressed high levels of COX-2 protein and mRNA relative to those of carcinoma tissues (Figs. 1Citation , 2Citation , and 4Citation ; Table 1Citation ). These findings are contrary to those described in other organs such as colon, stomach, esophagus, and lung. It was reported that the COX-2 level was higher in these tumors compared with nontumor tissues (18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28) . It is likely that the different results are attributable to the type of control tissue. In cases with liver, nontumor tissues were mostly pathological because of HCV-infected CH or cirrhosis. In support of this explanation, a low level of COX-2 mRNA was shown previously in the normal liver (42) , and we found that normal liver tissues devoid of viral infection showed little or no expression of COX-2.

In nonneoplastic liver tissues, we found a wide spectrum of COX-2 expression from normal liver to cirrhosis (Table 1)Citation . It appears from the present analysis that induction of COX-2 may be attributable to active inflammation in CH and cirrhotic livers (Table 3)Citation . This is reasonable, considering a fundamental action of COX-2 as a mediator of inflammation. Another mechanism for high induction of COX-2 in cirrhosis is that COX-2 might be induced to improve the ischemic/hypoxic microenvironment in the cirrhotic liver (47) . There is evidence that hypoxia can induce COX-2 (48) , and COX-2 facilitates angiogenesis via the enhanced release of angiogenic growth factors such as vascular endothelial growth factor (49) . Indeed, vascular endothelial growth factor level is increased in cirrhosis (50) .

It was of interest from a clinical point of view that an increase in COX-2 expression in the nontumor tissues was significantly associated with relapse of HCC (Fig. 3)Citation . The prognosis of HCC is generally unfavorable. Although primary tumors are curatively resected, 50–60% of patients suffer from the same disease within 5 years (51) . This could be because of either newly established tumor from the remnant liver, a process termed multicentric carcinogenesis (52) , or recurrence of the original tumor. One possible mechanism for a link between COX-2 and disease relapse is that high expression of COX-2 in the remnant liver might contribute to carcinogenesis, as proposed in other types of human carcinoma (29, 30, 31, 32, 33, 34) . Alternatively, COX-2 may enhance micrometastatic carcinoma cells to survive and spread after hepatectomy. The latter hypothesis is supported by several studies. For example, introduction of COX-2 cDNA into colon carcinoma cells facilitated growth (49) . COX-2 appears to prevent apoptosis because selective COX-2 inhibitors induced apoptosis in various cell culture systems (36, 37, 38) . Furthermore, it was shown that COX-2 promoted angiogenesis in malignant cells (49) .

Our immunohistochemical analysis indicated that COX-2 level was often high in cirrhotic livers; therefore, one may suppose that our striking data on prognosis might be because of the cirrhosis itself but not to COX-2 induction. We cannot rule out this possibility at present. However, of particular interest was that COX-2 expression was highly correlated with the presence of active inflammation (P < 0.0001). Furthermore, active inflammation in nontumor tissues has been shown to be associated with relapse of HCC (53, 54, 55) . Although administration of NSAIDs to patients with hepatitis or cirrhosis is generally not accepted because of a possible side effect of renal failure, it was demonstrated recently that a selective COX-2 inhibitor did not impair renal function in a rat model with liver cirrhosis (56) . Taken together, it would be important to examine whether selective COX-2 inhibitors may suppress inflammation and lead to better prognosis after hepatectomy for HCC.

Because there is direct evidence that dysplastic nodules (also designated as adenomatous hyperplasia) undergo neoplastic transformation (57) , these lesions are considered premalignant. In this study, seven of eight hepatic dysplasias (88%) expressed the COX-2 protein (Table 1)Citation . COX-2 overexpression in precancerous liver lesions is a finding similar to that seen in other tissues. For example, COX-2 is induced in colonic polyps, atypical adenomatous hyperplasia of the lung, and Barrett’s esophagus (18 , 22 , 23) . Furthermore, it has been demonstrated that selective COX-2 inhibitors prevent carcinogenesis in animal models (29, 30, 31, 32, 33, 34, 35, 36) . These findings strongly suggest that COX-2 may be involved in carcinogenesis of these organs. Recently, Denda et al. (58) demonstrated that administration of NSAIDs suppressed cirrhosis and subsequent formation of HCC in the choline-deficient, L-amino acid-defined rat model. To clarify whether COX-2 is a principle enzyme involved in liver carcinogenesis, in vivo animal studies are currently under way using a specific COX-2 inhibitor in our laboratory.

Our results in carcinoma tissues demonstrated a variable level of COX-2 expression among tissue samples. In 46 samples of HCCs, strong and moderate expressions of COX-2 were detected in 8 (17%) and 17 cases (37%), respectively, indicating that approximately one-half of HCC samples expressed the COX-2 protein (Table 1)Citation . From a therapeutic point of view, this finding is potentially important because several mechanistic studies indicated that carcinoma cells overexpressing COX-2, but not those cells lacking COX-2, are sensitive to COX-2 inhibitors (26 , 49 , 59) . On the other hand, a clinicopathological survey indicated that COX-2 expression was associated with low histological grade, i.e., differentiated phenotype (P = 0.019; Table 2Citation ). This result is consistent with those of recent studies indicating that COX-2 is induced during differentiation of human endometrial stromal cells and human keratinocytes, as well as HCCs (16 , 17 , 60 , 61) . It is known that early HCC is usually a differentiated carcinoma and that it gradually changes to poorly differentiated phenotype during tumor progression (62) . In this context, it is suggested that COX-2 may be associated with the early process of the progression of HCCs. This might be a reason for no correlation between COX-2 expression in HCC and patients’ prognoses.

In conclusion, we report here that COX-2 expression in nontumor was closely related to the postoperative relapse of HCC. This aspect is of clinical importance because there is a possibility that pharmacological inhibition of COX-2 activity might improve patients’ prognosis in the future, although further analysis of functional significance is essential.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a Grant-in Aid for Cancer Research from the Ministry of Health and Welfare of Japan and by an award (to H. Y.) from the Osaka Medical Research Foundation for Incurable Diseases. Back

2 To whom requests for reprints should be addressed, at Department of Surgery II, Osaka University Medical School, 2-2, Yamadaoka, Suita City, Osaka, 565-0871, Japan. Back

3 The abbreviations used are: HCC, hepatocellular carcinoma; NSAID, nonsteroidal anti-inflammatory drug; CH, chronic hepatitis; COX, cyclooxygenase; HCV, hepatitis C virus; PBGD, porphobilinogen deaminase; RT-PCR, reverse transcription-PCR; TAE, transarterial embolization. Back

Received 6/30/99; revised 9/ 8/99; accepted 9/ 8/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Colombo M. Hepatocellular carcinoma. J. Hepatol., 15: 225-236, 1992.[Medline]
  2. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology, 15: 948-963, 1992.[Medline]
  3. Ikeda K., Saito S., Koida I. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology, 18: 47-53, 1993.[Medline]
  4. Hla T., Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 89: 7384-7388, 1992.[Abstract/Free Full Text]
  5. Jones D. A., Carlton D. P., McIntyre T. M., Zimmerman G. A., Prescott S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.[Abstract/Free Full Text]
  6. Hamasaki Y., Kitzler J., Hardman R., Nettesheim P., Eling T. E. Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. Arch. Biochem. Biophys., 304: 226-234, 1993.[Medline]
  7. DuBois R. N., Awad J., Morrow J., Roberts L. N., Bishop P. R. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-{alpha} and phorbol ester. J. Clin. Investig., 93: 493-498, 1994.
  8. Kang R. Y., Freire M. J., Sigal E., Chu C. Q. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br. J. Rheumatol., 35: 711-718, 1996.[Abstract/Free Full Text]
  9. Singer I. I., Kawka D. W., Schloemann S., Tessner T., Riehl T., Stenson W. F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology, 115: 297-306, 1998.[Medline]
  10. Sawaoka H., Kawano S., Tsuji S., Tsuji M., Sun W., Gunawan E. S., Hori M. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukotrienes Essent. Fatty Acids, 59: 313-316, 1998.[Medline]
  11. Labayle D., Fischer D., Vielh P., Drouhin F., Pariente A., Bories C., Duhamel O., Trousset M., Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1991.[Medline]
  12. Thun M. J., Namboodiri M. M., Heath C. J. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325: 1593-1596, 1991.[Abstract]
  13. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 5: 138-146, 1994.[Medline]
  14. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc {delta}716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.[Medline]
  15. Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst., 90: 1609-1620, 1998.[Abstract/Free Full Text]
  16. Koga H., Sakiska S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., Harada M., Kusaba T., Tanaka M., Kimura R., Nakashima Y., Nakashima O., Kojiro M., Kurohiji T., Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 29: 688-696, 1999.[Medline]
  17. Shiota G., Okubo M., Noumi T., Noguchi N., Oyama K., Takano Y., Yashima K., Kishimoto Y., Kawasaki H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology, 46: 407-412, 1999.[Medline]
  18. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.[Medline]
  19. Sano H., Kawahito Y., Wilder R. L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55: 3785-3789, 1995.[Abstract/Free Full Text]
  20. Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57: 1276-1280, 1997.[Abstract/Free Full Text]
  21. Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Natl. Cancer Inst., 90: 455-460, 1998.[Abstract/Free Full Text]
  22. Wilson K. T., Fu S., Ramanujam K. S., Meltzer S. J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res., 58: 2929-2934, 1998.[Abstract/Free Full Text]
  23. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res., 58: 3761-3764, 1998.[Abstract/Free Full Text]
  24. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997-5001, 1998.[Abstract/Free Full Text]
  25. Fujita T., Matsui M., Takaku K., Uetake H., Ichikawa W., Taketo M. M., Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res., 58: 4823-4826, 1998.[Abstract/Free Full Text]
  26. Zimmermann K. C., Sarbia M., Weber A. A., Borchard F., Gabbert H. E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59: 198-204, 1999.[Abstract/Free Full Text]
  27. Tucker O. N., Dannenberg A. J., Yang E. K., Zhang F., Teng L., Daly J. M., Soslow R. A., Masferrer J. L., Woerner B. M., Koki A. T., Fahey T. R. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 59: 987-990, 1999.[Abstract/Free Full Text]
  28. Okami J., Yamamoto H., Fujiwara Y., Tsujie M., Kondo M., Noura S., Oshima S., Nagano H., Dono K., Umeshita K., Ishikawa O., Sakon M., Matsuura N., Nakamori S., Monden M. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res., 5: 2018-2024, 1999.[Abstract/Free Full Text]
  29. Vane J. Suppression of intestinal polyposis by inhibition of COX-2 in Apc knockout mice. Jpn. J. Cancer Res., 88: 1244-1245, 1997.
  30. Fukutake M., Nakatsugi S., Isoi T., Takahashi M., Ohta T., Mamiya S., Taniguchi Y., Sato H., Fukuda K., Sugimura T., Wakabayashi K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis (Lond.), 19: 1939-1942, 1998.[Abstract/Free Full Text]
  31. Nakatsugi S., Fukutake M., Takahashi M., Fukuda K., Isoi T., Taniguchi Y., Sugimura T., Wakabayashi K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res., 88: 1117-1120, 1997.[Medline]
  32. Kawamori T., Rao C. V., Seibert K., Reddy B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.[Abstract/Free Full Text]
  33. Reddy B. S., Rao C. V., Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.[Abstract/Free Full Text]
  34. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res., 58: 5354-5360, 1998.[Abstract/Free Full Text]
  35. Sheng H., Shao J., Kirkland S. C., Isakson P., Coffey R. J., Morrow J., Beauchamp R. D., DuBois R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Investig., 99: 2254-2259, 1997.[Medline]
  36. Hara A., Yoshimi N., Niwa M., Ino N., Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res., 88: 600-604, 1997.[Medline]
  37. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E. S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am. J. Physiol., 274: G1061-G1067, 1998.[Abstract/Free Full Text]
  38. Lui X. H., Yao S., Kirschenbaum A., Levine A. C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCaP cells. Cancer Res., 58: 4245-4249, 1998.[Abstract/Free Full Text]
  39. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.[Medline]
  40. Nagel S., Schmidt M., Thiede C., Huhn D., Neubauer A. Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res., 24: 4102-4103, 1996.[Abstract/Free Full Text]
  41. Chretien S., Dubart A., Beaupain D., Raich N., Grandchamp B., Rosa J., Goossens M., Romeo P. H. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc. Natl. Acad. Sci. USA, 85: 6-10, 1988.[Abstract/Free Full Text]
  42. O’Neill G. P., Ford H. A. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 330: 156-160, 1993.[Medline]
  43. Finke J., Fritzen R., Ternes P., Lange W., Dolken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques, 14: 448-453, 1993.[Medline]
  44. Ciaparrone M., Yamamoto H., Yao Y., Sgambato A., Cattoretti G., Tomita N., Monden T., Rotterdam H., Weinstein I. B. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res., 58: 114-122, 1998.[Abstract/Free Full Text]
  45. Short B. G., Zimmerman D. M., Schwartz L. W. Automated double labeling of proliferation and apoptosis in glutathione S-transferase-positive hepatocytes in rats. J. Histochem. Cytochem., 45: 1299-1305, 1997.[Abstract/Free Full Text]
  46. Yamamoto H., Soh J. W., Shirin H., Xing W. Q., Lim J. T., Yao Y., Slosberg E., Tomita N., Schieren I., Weinstein I. B. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells. Oncogene, 18: 103-115, 1999.[Medline]
  47. Morales-Ruiz M., Jimenez W., Perez Sala D., Ros J., Leivas A., Lamas S., Rivera F., Arroyo V. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology, 24: 1481-1486, 1996.[Medline]
  48. Schmedtje J. F., Jr., Ji Y. S., Liu W. L., DuBois R. N., Runge M. S. Hypoxia induces cyclooxygenase-2 via the NF-{kappa}B p65 transcription factor in human vascular endothelial cells. J. Biol. Chem., 272: 601-608, 1997.[Abstract/Free Full Text]
  49. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.[Medline]
  50. El-Assal O. N., Yamanoi A., Yamaguchi M., Igarashi M., Yamamoto A., Nabika T., Nagasoe N. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factors in angiogenesis of cirrhotic liver. Hepatology, 27: 1554-1562, 1998.[Medline]
  51. Wu C. C., Chen J. T., Ho W. L., Yeh D. C., Tang J. S., Liu T. J., P’eng F. K. Liver resection for hepatocellular carcinoma in octogenarians. Surgery, 125: 332-338, 1999.[Medline]
  52. Tarao K., Hoshino H., Shimizu A., Ohkawa S., Nakamura Y., Harada M., Ito Y., Tamai S., Akaike M., Sugimasa Y. Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn. J. Cancer Res., 85: 1040-1044, 1994.[Medline]
  53. Tarao K., Takemiya S., Tamai S., Sugimasa Y., Ohkawa S., Akaike M., Tanabe H., Shimizu A., Yoshida M., Kakita A. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer (Phila.), 79: 688-694, 1997.[Medline]
  54. Ko S., Nakajima Y., Kanehiro H. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Ann. Surg., 224: 591-595, 1996.[Medline]
  55. Ko S., Nakajima Y., Kanehiro H., Kin T., Aomatsu Y., Yoshimura A., Taki J., Yagura K., Ohashi K., Nakano H. Influence of associated viral hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. World J. Surg., 21: 1082-1086, 1996.
  56. Bosch-Marce M., Claria J., Titos E., Masferrer J. L., Altuna R., Poo J. L., Jimenez W., Arroyo V., Rivera F., Rodes J. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology, 116: 1167-1175, 1999.[Medline]
  57. Takayama T., Makuuchi M., Hirohashi S., Sakamoto M., Okazaki N., Takayasu K., Kosuge T., Motoo Y., Yamazaki S. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet, 336: 1150-1153, 1990.[Medline]
  58. Denda A., Endoh T., Kitayama W., Tang Q., Noguchi O., Kobayashi Y., Akai H., Okajima E., Tsujiuchi T., Tsutsumi M., Nakae D., Konishi Y. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L -amino acid-defined diet in rats. Carcinogenesis (Lond.), 18: 1921-1930, 1997.[Abstract/Free Full Text]
  59. Goldman A. P., Williams C. S., Sheng H., Lamps L. W., Williams V. P., Pairet M., Morrow J. D., DuBois R. N. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis (Lond.), 19: 2195-2199, 1998.[Abstract/Free Full Text]
  60. Bracken K. E., Elger W., Jantke I., Nanninga A., Gellersen B. Cloning of guinea pig cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase complementary deoxyribonucleic acids: steroid-modulated gene expression correlates to prostaglandin F2{alpha} secretion in cultured endometrial cells. Endocrinology, 138: 237-247, 1997.[Abstract/Free Full Text]
  61. Leong J., Hughes Fulford M., Rakhlin N., Habib A., Maclouf J., Goldyne M. E. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp. Cell Res., 224: 79-87, 1996.[Medline]
  62. Sugihara S., Nakashima O., Kojiro M., Majima Y., Tanaka M., Tanikawa K. The morphologic transition in hepatocellular carcinoma: a comparison of the individual histologic features disclosed by ultrasound-guided fine-needle biopsy with those of autopsy. Cancer (Phila.), 70: 1488-1492, 1992.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Han, G. Li, K. Lim, M. C. DeFrances, C. R. Gandhi, and T. Wu
Transgenic Expression of Cyclooxygenase-2 in Hepatocytes Accelerates Endotoxin-Induced Acute Liver Failure
J. Immunol., December 1, 2008; 181(11): 8027 - 8035.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A. P Holt and D. H Adams
Complex roles of cyclo-oxygenase 2 in hepatitis
Gut, July 1, 2007; 56(7): 903 - 904.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Kiguchi, L. Ruffino, T. Kawamoto, E. Franco, S.-i. Kurakata, K. Fujiwara, M. Hanai, M. Rumi, and J. DiGiovanni
Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice
Mol. Cancer Ther., June 1, 2007; 6(6): 1709 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Xu, C. Han, K. Lim, and T. Wu
Cross-talk between Peroxisome Proliferator-Activated Receptor {delta} and Cytosolic Phospholipase A2{alpha}/Cyclooxygenase-2/Prostaglandin E2 Signaling Pathways in Human Hepatocellular Carcinoma Cells
Cancer Res., December 15, 2006; 66(24): 11859 - 11868.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. A. Davies, B. Knight, Y. W. Tian, G. C.T. Yeoh, and J. K. Olynyk
Hepatic oval cell response to the choline-deficient, ethionine supplemented model of murine liver injury is attenuated by the administration of a cyclo-oxygenase 2 inhibitor
Carcinogenesis, August 1, 2006; 27(8): 1607 - 1616.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Cui, C.-H. Yu, and K.-Q. Hu
In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells
Clin. Cancer Res., November 15, 2005; 11(22): 8213 - 8221.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. B. Thomas and J. L. Abbruzzese
Opportunities for Targeted Therapies in Hepatocellular Carcinoma
J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, and J. DiGiovanni
Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5572 - 5580.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Mayoral, A. Fernandez-Martinez, L. Bosca, and P. Martin-Sanz
Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells
Carcinogenesis, April 1, 2005; 26(4): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
N A Mohammed, S A El-Aleem, H A El-Hafiz, and R F T McMahon
Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis
J. Clin. Pathol., April 1, 2004; 57(4): 350 - 354.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
W. E. Hardman
Omega-3 Fatty Acids to Augment Cancer Therapy
J. Nutr., November 1, 2002; 132(11): 3508S - 3512.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
J. M. Wallace
Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy
Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
A. Denda, W. Kitayama, A. Murata, H. Kishida, Y. Sasaki, O. Kusuoka, T. Tsujiuchi, M. Tsutsumi, D. Nakae, H. Takagi, et al.
Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide
Carcinogenesis, February 1, 2002; 23(2): 245 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang
Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations
Cancer Res., June 1, 2001; 61(11): 4375 - 4381.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. N. DuBois
Cyclooxygenease-2 and Hepatocellular Carcinoma: Is It a Target for Prevention?
Clin. Cancer Res., May 1, 2001; 7(5): 1110 - 1110.
[Full Text]

Home page
 Clin. Cancer Res.